What is Going on with GMTX?
On May 1, 2021, Gemini Therapeutics (GMTX) released its preclinical data for its GEM103 therapy at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting. GEM103 is currently in clinical development to treat patients with geographic atrophy (GA) secondary to dry AMD and as add-on therapy for patients with other ocular disorders (such as wed AMD with macular atrophy risk and who are receiving anti-VEGF treatment). Gemini Therapeutics’ data demonstrates that human recombinant Complement Factor H (rhCFH) was able to reduce the severity of CNV as compared to the control group. Shares of GMTX were up 1.54% to $11.87 a share Monday morning.
Today, Gemini Therapeutics has announced its appointment of Georges Gemayel as the Chair of Board of Directors. Gemini Therapeutics’ CEO, Jason Meyenburg expressed that he is, “pleased to welcome Georges to Gemini’s Board of Directors during this important time in our Company’s maturation, as we advance our lead program into the next stages of clinical development,” and that, “Georges’ broad management experience and proven track record of commercial and product development success will be invaluable as we continue to advance our pipeline of novel precision medicines.”
What This Means for GMTX?
The results of their data is promising for future research into GEM103. As Walter Strapps, CSO at Gemini Therapeutics states, “the results presented demonstrate that GEM103 may be the next generation of complement therapeutics that is differentiated by both its mode of action and its potential for an improved safety profile. These data are part of the growing body of evidence contributing to our confidence in GEM103’s development as a novel intravitreal treatment to restore regulation of the complement system and potentially benefit patients with AMD.”
Going forward, perhaps the appointment of Georges Gemayel will also be instrumental in the advancement of this research. Georges Gemayel states that, "Gemini has a very exciting approach to treat dry AMD that could bring to the market a best-in-class product,” and that he looks, “forward to working with management and with my fellow directors to advance Gemini and the Company’s innovative pipeline of precision medicine therapeutic candidates.”
GMTX has an Overall Score of 35. Find out what this means to you and get the rest of the rankings on GMTX!
Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health.
